PT  - JOURNAL ARTICLE
AU  - Wim A Wuyts
AU  - Arata Azuma
AU  - Jörg H W Distler
AU  - Klaus Sondergaard
AU  - Susanna Proudman
AU  - Vincent Cottin
AU  - Elvira Erhardt
AU  - Manuel Quaresma
AU  - Martina Gahlemann
AU  - Margarida Alves
AU  - Toby M Maher
TI  - Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function
AID  - 10.1183/13993003.congress-2020.3393
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 3393
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/3393.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/3393.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Introduction: In the SENSCIS trial in patients with systemic sclerosis-associated ILD (SSc-ILD), nintedanib reduced the rate of decline in FVC over 52 weeks compared with placebo.Aim: Assess the effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function.Methods: We analysed the rate of decline in FVC (mL/year) over 52 weeks in subgroups with FVC ≤90% vs >90% predicted and FVC ≤60% vs >60% predicted at baseline in the SENSCIS trial.Results: Of 576 patients treated with nintedanib or placebo, 14.1% had FVC >90% predicted and 26.2% had FVC ≤60% predicted at baseline. The rate of decline in FVC in the placebo group was numerically greater in patients with FVC ≤90% than >90% predicted and in patients with FVC ≤60% than >60% predicted (Figure).The effect of nintedanib vs placebo on reducing the rate of decline in FVC was similar between patients with FVC ≤90% vs >90% predicted (Figure). The effect of nintedanib vs placebo on reducing the rate of decline in FVC was numerically more pronounced in patients with FVC >60% than ≤60% predicted, but the exploratory interaction p-value did not indicate heterogeneity in the treatment effect between subgroups (Figure).Conclusion: In the SENSCIS trial, the benefit of nintedanib on reducing the rate of decline in FVC was consistent in patients with preserved FVC and in patients with advanced impairment in FVC at baseline. FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3393.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).